Skip to main content

Current status of fibrosis markers.

Publication ,  Journal Article
Patel, K; Shackel, NA
Published in: Curr Opin Gastroenterol
May 2014

PURPOSE OF REVIEW: Improved understanding of the pathophysiology of fibrosis and recent technological advances have resulted in the development of several serum biomarkers and imaging tools as noninvasive alternatives to biopsy. Most of these markers have been developed in chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD) patients. This review highlights some of the recent advances and potential clinical application of these modalities. RECENT FINDINGS: Many noninvasive approaches initially developed for binary disease staging in CHC continue to be refined for diagnostic use in other chronic liver disease such as NAFLD. A combination of serum markers and imaging tools appears useful in reducing the need for biopsy for the diagnosis of cirrhosis, and providing functional assessment in advanced stage disease. Cytokeratin-18 fragments, controlled attenuation parameter (CAP), real-time elastography, and magnetic resonance imaging approaches appear promising for NAFLD, but require further validation. SUMMARY: Current noninvasive tests of fibrosis provide good diagnostic and prognostic utility for advanced stage liver disease, and have been adapted into clinical practice for CHC. Reliable biomarkers for steatosis, nonalcoholic steatohepatitis, and assessment of fibrosis progression in chronic liver disease are still required. Continued advances in bioimaging and functional genomics will be important for quantitative assessment of fibrosis and future biomarker development.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin Gastroenterol

DOI

EISSN

1531-7056

Publication Date

May 2014

Volume

30

Issue

3

Start / End Page

253 / 259

Location

United States

Related Subject Headings

  • Prognosis
  • Non-alcoholic Fatty Liver Disease
  • Liver Cirrhosis
  • Liver
  • Humans
  • Gastroenterology & Hepatology
  • Elasticity Imaging Techniques
  • Disease Progression
  • Biopsy
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, K., & Shackel, N. A. (2014). Current status of fibrosis markers. Curr Opin Gastroenterol, 30(3), 253–259. https://doi.org/10.1097/MOG.0000000000000059
Patel, Keyur, and Nicholas A. Shackel. “Current status of fibrosis markers.Curr Opin Gastroenterol 30, no. 3 (May 2014): 253–59. https://doi.org/10.1097/MOG.0000000000000059.
Patel K, Shackel NA. Current status of fibrosis markers. Curr Opin Gastroenterol. 2014 May;30(3):253–9.
Patel, Keyur, and Nicholas A. Shackel. “Current status of fibrosis markers.Curr Opin Gastroenterol, vol. 30, no. 3, May 2014, pp. 253–59. Pubmed, doi:10.1097/MOG.0000000000000059.
Patel K, Shackel NA. Current status of fibrosis markers. Curr Opin Gastroenterol. 2014 May;30(3):253–259.

Published In

Curr Opin Gastroenterol

DOI

EISSN

1531-7056

Publication Date

May 2014

Volume

30

Issue

3

Start / End Page

253 / 259

Location

United States

Related Subject Headings

  • Prognosis
  • Non-alcoholic Fatty Liver Disease
  • Liver Cirrhosis
  • Liver
  • Humans
  • Gastroenterology & Hepatology
  • Elasticity Imaging Techniques
  • Disease Progression
  • Biopsy
  • Biomarkers